LONDON: RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company focusing on high-growth potential assets in the life sciences sector, has announced a new investment in Alesta Therapeutics.
The Netherlands-based biotechnology firm, Alesta, is dedicated to developing novel oral small molecule therapies for rare, underserved diseases.
Alesta Therapeutics recently completed a €65 million (US$67 million) Series A financing round, with participation from RTW Biotech Opportunities Ltd and other investment vehicles managed by RTW Investments, LP.
The newly raised funds will be used to advance Alesta’s lead asset, ALE1, aimed at treating hypophosphatasia (HPP), a rare genetic disorder, toward clinical proof of concept. Additionally, the financing will accelerate the development of a second asset, ALE2, a promising candidate for Charcot-Marie-Tooth (CMT) disease.
Roderick Wong, Managing Partner and CIO at RTW Investments, LP, expressed excitement about the investment, stating, “We are thrilled to participate in Alesta’s Series A round. The innovative approach and compelling preclinical data for ALE1 demonstrate significant potential to address critical unmet needs in rare diseases. We are eager to support Alesta’s journey and its efforts to bring transformative therapies to patients who need them most.”
RTW Biotech Opportunities invests in Mirador Therapeutics and Santa Ana Bio